CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening, BL West… - Cancer research, 2014 - AACR
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer …, 2014 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Cancer immunotherapy generally offers limited
clinical benefit without coordinated strategies to mitigate the immunosuppressive nature of …

[PDF][PDF] CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer …

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer Res, 2014 - researchgate.net
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer …, 2014 - profiles.wustl.edu
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

[PDF][PDF] CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer …

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening, BL West… - Cancer Res, 2014 - academia.edu
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Y Zhu, BL Knolhoff, MA Meyer… - Cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer …, 2014 - europepmc.org
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

[HTML][HTML] CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T Cell Checkpoint Immunotherapy in Pancreatic Cancer …

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer …, 2014 - ncbi.nlm.nih.gov
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

[PDF][PDF] CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer …

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer Res, 2014 - roswellpark.org
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Y Zhu, BL Knolhoff, MA Meyer, TM Nywening… - Cancer …, 2014 - europepmc.org
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …